About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.
- Order Number
- Package Size
- 100 µl (10 Tests)
XL TET2 consists of an orange-labeled probe hybridizing to the TET2 gene region at 4q24 and a green-labeled probe hybridizing to 4q12.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).
A minimally deleted region on chromosome 4q24 is described in subgroups of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). The region encompasses the TET2 gene. The frequency of TET2 mutations in unselected patients was 19% (15 of 81 patients) with myelodysplastic syndromes, 12% (24 of 198 patients) with myeloproliferative disorders, 24% (5 of 21 patients) with secondary AML, and 22% (2 of 9 patients) with chronic myelomonocytic leukemia.
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)
- Chronic Myelogenous Leukemia (CML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating a deletion of TET2 (4q24).
- Jankowska et al (2009) Blood 113:6403-6410
- Delhommeau et al (2009) N Engl J Med 360:2289-2301
- Flach et al (2010) Haematologica 95:518-519